Resilient Sanofi stock rides FDA approval of updated COVID vaccine
Published on 08/29/2026 at 07:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sanofi stock, tied to the French healthcare group Sanofi (FR0000127771), is drawing renewed attention after US regulators approved an updated version of its Nuvaxovid COVID-19 vaccine for the 2026-2027 immunization season as of August 28, 2026. The approval supports Sanofi's position in the respiratory vaccines market at a time when consensus earnings forecasts for 2026 and 2027 have been nudged higher per recent analyst data.
FDA clears updated Nuvaxovid for high-risk adults
According to a detailed overview of new COVID-19 shots, the Food and Drug Administration has signed off on updated vaccines from multiple manufacturers for the upcoming season, including Sanofi's Nuvaxovid formulation originally licensed from Novavax. One recent report explains that Nuvaxovid is now approved for adults aged 65 years and older as well as people between 12 and 64 years who face a high risk of severe COVID-19, defining a focused target group for the shot.
A separate news summary on updated vaccines for the 2026-2027 season points out that the FDA decision covers formulations calibrated to newer variants, with Sanofi involved through its participation in the Novavax-Sanofi partnership for this protein-based vaccine. The coverage underscores that the protein-based approach offers an alternative to mRNA platforms for individuals who prefer or medically require a different technology.
From an investor's standpoint, this regulatory step matters because it gives Sanofi a defined, high-risk patient population for Nuvaxovid heading into the 2026-2027 season, creating the potential for incremental revenue streams within its vaccines portfolio. It also signals that regulators continue to view protein-based vaccines as part of a diversified long-term toolkit for COVID-19 protection.
Earnings estimates edge higher for 2026 and 2027
On the earnings side, recent analyst consensus data show modest upward revisions to Sanofi's per-share profit expectations over the next two years. One technical and earnings-focused analysis notes that the 2026 earnings-per-share estimate has moved from $4.96 to $5.01 during the past 30 days, while the 2027 estimate has increased from $5.19 to $5.23 in the same period.
The shifts are small in absolute terms but meaningful as a signal: the 2026 EPS projection has risen by $0.05 and the 2027 value by $0.04 over a relatively short window, implying that covering analysts are incrementally more confident in Sanofi's ability to deliver profit growth. For shareholders, such revisions often reflect a combination of stable core franchises and ongoing cost discipline.
The same analysis highlights that Sanofi's stock performance has lagged its broader healthcare peer group on a year-to-date basis, showing a decline of 7.5% compared with a 16.0% gain for the relevant industry index. That 23.5-percentage-point gap underscores a valuation backdrop where improving earnings expectations may not yet be fully reflected in the share price.
Technical backdrop and medium-term positioning
From a chart perspective, recent market commentary observes that Sanofi stock is trading above both its 50-day and 200-day simple moving averages. While exact price levels are not provided in the available snapshot, the position above these medium- and long-term trend indicators is typically viewed as a constructive sign for momentum-oriented investors.
A stock holding above its 50-day and 200-day moving averages indicates that the current price stands higher than the average closing levels that prevailed over the past several weeks and several months. For Sanofi, that configuration suggests that buying interest has been sufficient to keep the shares on an upward technical path even as fundamental questions around certain vaccine segments remain.
At the same time, the divergence between weaker share performance year to date and stronger underlying moving-average readings hints at a period of recovery after earlier declines. If earnings estimates continue to firm and regulatory catalysts like the Nuvaxovid approval translate into tangible revenue contributions, the technical structure could provide a base for a more sustained rerating.
Dupixent and vaccines frame the fundamental story
Beyond COVID-19, Sanofi's medium-term prospects are heavily influenced by its specialty-care franchise, particularly the biologic therapy Dupixent, which is widely seen as a key driver of top-line growth. Recent research commentary states that Dupixent remains a central contributor to Sanofi's revenue trajectory thanks to strong demand across indications in inflammatory and allergic diseases.
The same commentary points out that influenza vaccines and certain pipeline projects have faced headwinds, reminding investors that Sanofi's portfolio mix still carries exposure to more cyclical segments. In that context, the Nuvaxovid approval offers diversification within vaccines and adds another potential pillar alongside influenza and pediatric immunization products.
For long-term holders, the combination of a growing specialty-care base and a more balanced vaccine portfolio is crucial. It suggests that while individual segments may face pressure from competition or pricing dynamics, the overall earnings engine is supported by multiple franchises with differing regulatory cycles and demand drivers.
Representative product: Nuvaxovid COVID-19 vaccine
A representative example of Sanofi's recent innovation push is Nuvaxovid, its protein-based COVID-19 vaccine developed under license from Novavax and now approved in the United States for high-risk populations. The detailed vaccine overview notes that Nuvaxovid does not rely on mRNA technology but instead uses a traditional protein subunit approach, which may appeal to patients and clinicians seeking an alternative modality.
With an indication centered on adults aged 65 and older, as well as younger individuals deemed at high risk of severe disease, Nuvaxovid is positioned as a targeted solution rather than a mass-market seasonal booster. That focus can still translate into meaningful demand, given the continuing burden of severe COVID-19 cases among vulnerable groups and the need for updated vaccinations aligned with new variants.
For Sanofi, the product's regulatory status adds another lever in its vaccines business, complementing existing lines in influenza, pediatric immunization, and other infectious diseases. While precise sales forecasts for the 2026-2027 season are not detailed in the sources at hand, investors will be watching how quickly Nuvaxovid gains traction and whether subsequent data support broader use or label expansions.
Stock perspective and current market context
With the FDA decision dated August 28, 2026, Sanofi enters the late-summer period with a clearer regulatory roadmap for its COVID-19 offering. The incremental upgrades to 2026 and 2027 EPS estimates suggest that analysts are beginning to reflect this and other operational factors in their models, even though the share price performance year to date has lagged the wider healthcare space.
For investors, the key questions now revolve around conversion of regulatory approvals into revenue, the durability of Dupixent-led growth, and the extent to which weaker areas like influenza vaccines can be stabilized or repositioned. Technical support from trading above key moving averages offers some reassurance for those focused on price trends, but the longer-term trajectory will depend on execution across Sanofi's diversified portfolio.
Read more
Further background on Sanofi stock and its earnings consensus, including detailed commentary on moving averages and sector comparisons, can be found in the recent technical and earnings analysis referenced above. The FDA-focused vaccine reports cited earlier provide deeper insight into the positioning of Nuvaxovid within the updated COVID-19 immunization landscape for 2026-2027.
Sanofi at a glance
Company: Sanofi
ISIN: FR0000127771
Ticker: SNY
Exchange: Euronext Paris, ADR on Nasdaq
Sector / Industry: Health care - Pharmaceuticals
Index membership: CAC 40
